Current Edition

Interview with Lawrence Friedhoff of Axovant Sciences

JCS speaks with Lawrence Friedhoff, the Chief Development Officer of Axovant Sciences, about his involvement with the development of Donepezil, the most widely-used drug for the treatment of Alzheimer’s.